RxDoctor Payments Data

Sammy Cox, MD

Cardiovascular Disease · Amarillo, TXNPI 1659312775

Payments from drug & device makers

$367,317in general payments, 2019–2025

Across 327 payments — averaging $1123.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • American Regent$312K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$25K
  • Abbott$14K
  • Astrazeneca UK Limited$9K
  • Biotronik Inc.$3K
  • Abiomed$3K
  • plus $2K from 17 others

What the payments were for

  • Travel & lodging$1,61217%
  • Food & beverage$7,93482%
  • Education$1522%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$367,317 in reported general payments places this provider in the 95th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$1,633,837
Medicare patients
3,034
Services billed
17,913

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban862$819,927
EntrestoSacubitril/Valsartan133$129,184
XareltoRivaroxaban93$99,902
JardianceEmpagliflozin81$77,732
Repatha SureclickEvolocumab69$54,858
BrilintaTicagrelor65$41,910
MultaqDronedarone Hcl24$28,006
Metoprolol Succinate738$12,133
Praluent PenAlirocumab16$11,848
Atorvastatin Calcium1,053$10,628
Valsartan215$6,773
Potassium Chloride246$5,496
Rosuvastatin Calcium430$5,276
Carvedilol604$4,960
Losartan Potassium417$4,449

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$127$819,927862 claims
NovartisEntresto$80$129,184133 claims
Boehringer IngelheimJardiance$46$77,73281 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Amarillo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →